文献速递基础与转化研究临床试验与 GCP

间皮素靶向免疫毒素LMB-100联合抗PD-1抗体在间皮瘤患者和小鼠肿瘤模型中疗效增强

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
PubMed 文献 · Sci Transl Med · 2020-01-01

该研究观察了LMB-100治疗后进展的间皮瘤患者接受PD-1抑制剂治疗的应答,并建立小鼠模型探讨LMB-100是否增强肿瘤对PD-1阻断的敏感性。10例患者客观缓解率为40%,中位总生存11.9个月;可评估7例中4例客观缓解。PD-L1阳性患者无进展生存显著延长(11.3 vs 2.1个月,P=0.0018)。

要点

  • LMB-100后序贯PD-1抑制剂在间皮瘤中客观缓解率40%,中位总生存11.9个月
  • 肿瘤PD-L1阳性者客观缓解4/5,无进展生存11.3 vs 2.1个月(P=0.0018)
  • LMB-100引起全身炎症反应并招募CD8+ T细胞进入肿瘤

核心结论

  • LMB-100治疗后进展的间皮瘤患者接受PD-1抑制剂可出现客观肿瘤缓解,PD-L1阳性者获益更明显。
  • 小鼠模型支持LMB-100联合抗PD-1抗体具有增强的抗肿瘤效应。

研究设计与样本

  • 回顾性分析10例LMB-100治疗后进展并接受PD-1抑制剂(帕博利珠单抗9例,纳武利尤单抗1例)的间皮瘤患者。
  • 建立人外周血单个核细胞移植间皮瘤小鼠模型和人间皮素表达同基因肺腺癌小鼠模型研究联合效应。

主要发现

  • 10例患者客观肿瘤缓解率为40%,中位总生存11.9个月。
  • 可评估7例中4例客观缓解,包括1例完全缓解和3例部分缓解,总生存分别为39.0+、27.7、32.6+和13.8个月。
  • PD-L1表达分层:5例PD-L1阳性中4例客观缓解;PD-L1阳性者无进展生存11.3 vs 2.1个月(P=0.0018)。
  • 总生存27.7 vs 6.8个月(P=0.1),无统计学显著差异。
  • LMB-100引起全身炎症反应并招募CD8+ T细胞至患者肿瘤。

关键数值与推荐

  • 客观肿瘤缓解率40%(10例接受PD-1抑制剂患者)。
  • PD-L1阳性者无进展生存11.3个月 vs PD-L1阴性者2.1个月,P=0.0018。
  • PD-L1阳性者总生存27.7个月 vs PD-L1阴性者6.8个月,P=0.1。

临床怎么用

  • 间皮瘤患者LMB-100治疗后进展可考虑序贯PD-1抑制剂,尤其肿瘤PD-L1阳性者。
  • LMB-100联合帕博利珠单抗正在间皮瘤患者的前瞻性临床试验中评估。

局限性

  • 患者样本量小(10例),可评估者仅7例,结论需前瞻性试验验证。
  • PD-1抑制剂为方案外用药,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

LMB-100 is an immunotoxin targeting the cell surface protein mesothelin, which is highly expressed in many cancers including mesothelioma. Having observed that patients receiving pembrolizumab off protocol after LMB-100 treatment had increased tumor responses; we characterized these responses and developed animal models to study whether LMB-100 made tumors more responsive to antibodies blocking programmed cell death protein 1 (PD-1). The overall objective tumor response in the 10 patients who received PD-1 inhibitor (pembrolizumab, 9; nivolumab, 1) after progression on LMB-100 was 40%, and the median overall survival was 11.9 months. Of the seven evaluable patients, four had objective tumor responses, including one complete response and three partial responses, and the overall survival for these patients was 39.0+, 27.7, 32.6+, and 13.8 months. When stratified with regard to programmed death ligand 1 (PD-L1) expression, four of five patients with tumor PD-L1 expression had objective tumor response. Patients with positive tumor PD-L1 expression also had increased progression-free survival (11.3 versus 2.1 months, P = 0.0018) compared with those lacking PD-L1 expression. There was no statistically significant difference in overall survival (27.7 versus 6.8 months, P = 0.1). LMB-100 caused a systemic inflammatory response and recruitment of CD8+ T cells in patients' tumors. The enhanced antitumor effects with LMB-100 plus anti-PD-1 antibody were also observed in a human peripheral blood mononuclear cell-engrafted mesothelioma mouse model and a human mesothelin-expressing syngeneic lung adenocarcinoma mouse model. LMB-100 plus pembrolizumab is now being evaluated in a prospective clinical trial for patients with mesothelioma.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Jiang Q, Ghafoor A, Mian I, et al. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med. 2020. PMID: 32611684. doi:10.1126/scitranslmed.aaz7252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。